Výsledky vyhledávání - "Bertrand Alluis"

Better glycaemic control with BioChaperone glargine lispro co‐formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes

Autor: Grégory Meiffren, Oliver Klein, Claire Mégret, Olivier Soula, Tim Heise, Martin Gaudier, Ernestos Anastassiadis, Leona Plum-Mörschel, Bertrand Alluis, J. Hans DeVries, Theresa Herbrand

Publikováno v: Diabetes, obesity & metabolism, 21(7), 1570-1575. Wiley-Blackwell

Because of its physico-chemical properties, insulin glargine is usually not mixable with rapid insulins. BioChaperone BC147 is a polyanionic amphiphilic polymer, solubilizing insulin glargine at neutral pH, and thus enabling stable glargine formulati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::925d213202eeedf3511253608e3db5bc
https://doi.org/10.1111/dom.13685

Zobrazit plný text záznamu

BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study

Autor: Aymeric Ranson, Jorge Arrubla, Bruce W. Bode, Grégory Meiffren, Olivier Soula, Martin Gaudier, Cyril Seroussi, José Correia, Bertrand Alluis, Oliver Klein, Rémi Soula, Tim Heise, J. Hans DeVries

Publikováno v: Diabetes, Obesity and Metabolism. 21:1066-1070

We investigated the pharmacodynamics (PD) and pharmacokinetics (PK) of BioChaperone insulin Lispro (BCLIS), faster insulin aspart (FIA) and insulin aspart (ASP) in patients with type 1 diabetes using an insulin pump. In this randomized, double-blind,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b93e4bd3b85e1c76537a1b94e6a00f8
https://doi.org/10.1111/dom.13621

Zobrazit plný text záznamu

Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes

Autor: Aymeric Ranson, Martin Gaudier, Cyril Seroussi, Tim Heise, Bertrand Alluis, J. Hans DeVries, Grit Andersen, Grégory Meiffren, Olivier Soula, Daniela Lamers

Publikováno v: Diabetes, obesity & metabolism, 20(11), 2627-2632. Wiley-Blackwell

Aim To investigate the safety and efficacy of BioChaperone Lispo (BCLIS), an ultra-rapid formulation of insulin lispro (LIS) in people with type 1 diabetes. Materials and methods In this randomized, double-blind study, participants self-administered

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a52850006e4ff4297552d935246edd84
https://doi.org/10.1111/dom.13442

Zobrazit plný text záznamu

Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-rapid Insulin BioChaperone Lispro (BCLIS) vs. Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes

Autor: Grégory Meiffren, Olivier Soula, Martin Gaudier, Eric Zijlstra, Stanislav Glezer, Tim Heise, Aymeric Ranson, Bertrand Alluis

Publikováno v: Diabetes. 67

BCLIS is an ultra-rapid insulin lispro formulation designed to accelerate the time-action profile vs. conventional short-acting insulin analogs. PK characteristics of single doses of BCLIS and LIS were characterized in four randomized, double-blind,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2287164ad8ff4a2b1222d7019bddb33
https://doi.org/10.2337/db18-998-p

Zobrazit plný text záznamu

The Ultra-rapid Insulin (URI) BioChaperone Lispro (BCLIS) Shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs. Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)

Autor: Tim Heise, Rémi Soula, Grégory Meiffren, Aymeric Ranson, Olivier Soula, Martin Gaudier, Bruce W. Bode, Stanislav Glezer, Jorge Arrubla, Cyril Seroussi, José Correia, Bertrand Alluis, Oliver Klein

Publikováno v: Diabetes. 67

This double-blind randomized crossover trial is the first to compare the PD and PK properties of two URIs (BCLIS and FIA) and of a conventional analog (ASP). Forty-three patients with type 1 diabetes received a bolus of 0.15 U/kg of BCLIS, FIA or ASP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::907bc00c45f283fcdd0b8c1227c45f6e
https://doi.org/10.2337/db18-1035-p

Zobrazit plný text záznamu

BioChaperone 222 (BC222), the New Excipient Enabling the Ultra-rapid BioChaperone Lispro (BCLIS) Formulation, Is Completely Absorbed and Rapidly Excreted after Subcutaneous (s.c.) Injection

Autor: Aymeric Ranson, Grégory Meiffren, Olivier Soula, Martin Gaudier, Ernestos Anastassiadis, Grit Andersen, Stanislav Glezer, Cyril Seroussi, José Correia, Leona Plum-Moerschel, Bertrand Alluis

Publikováno v: Diabetes. 67

BC222 is an oligosaccharide grafted with anionic charges and amino acid moieties designed to speed up the absorption of insulin lispro in the BCLIS formulation. Non-clinical data indicated that BC222 is rapidly excreted unchanged by the kidney. This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06dec05fec38d3079d5ad3eca48c2ad7
https://doi.org/10.2337/db18-1024-p

Zobrazit plný text záznamu

BioChaperone Technology Enables the Development of Pramlintide-Prandial Insulin Combinations

Autor: Grégory Meiffren, Olivier Soula, Aymeric Ranson, Yves Meyer, Bertrand Alluis, Richard Charvet, Rémi Soula, Charles Fortier, Alexandre Geissler

Publikováno v: Diabetes. 67

Pramlintide (Symlin®) is currently used on top of mealtime insulin therapy by T1D or T2D patients to achieve a better control of post-prandial glucose excursion. Indeed, pramlintide affects the rate of postprandial glucose appearance by slowing down

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8acf9c8445df2a91ddb3907416847eae
https://doi.org/10.2337/db18-349-or

Zobrazit plný text záznamu

Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell)

Autor: Florence Meyer-Losic, Vincent Dubois, Jonathan Kearsey, Matthieu Michel, Françoise Cailler, Jérôme Quinonero, Mireille Dechambre, Anne-Marie Fernandez, and André Trouet, Bertrand Alluis

Publikováno v: Journal of Medicinal Chemistry. 49:6908-6916

Improvement in the therapeutic index of doxorubicin, a cytotoxic molecule, has been sought through its chemical conjugation to short (15-23 amino acid) peptide sequences called Vectocell peptides. Vectocell peptides are highly charged drug delivery p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b552b8f1f6c5bcd87a1c0c0f2af080
https://doi.org/10.1021/jm0606591

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání